HC Wainwright Initiates Aptorum On Upcoming “Innovative Pipeline”
HC Wainwright initiated coverage on Aptorum Group Limited (NASDAQ:APM) with a Buy rating and a price target of $8. The analyst is…
Pfizer’s Partner BioNTech Signs Research Pact With Australia
Pfizer Inc’s (NYSE:PFE) COVID-19 partner BioNTech SE (NASDAQ:BNTX) will set up research and manufacturing centers in Australia. BioNTech and Australia’s Victoria state signed…
Rebound In COVID-19 Symptoms After Pfizer’s Antiviral Pill Might Be Due To Stronger Immune Response
Reports are circulating related to recurring COVID-19 symptoms after completing treatment and experiencing improvement after Pfizer Inc’s (NYSE:PFE) COVID-19 oral antiviral…
CVS Health Stock Falls After Change In Medicare Star Ratings
The Centers for Medicare & Medicaid Services released its 2023 Star Ratings for Medicare Advantage (Medicare Part C) and Medicare Part D prescription drug plans.
Cannabinoids & Autism Spectrum Disorder: This Baltimore Company Is On Track To Start Phase 2 Clinical Trial For New Treatment
Cannabinoid-focused biopharmaceutical company Greater Cannabis Company, Inc. (OTC: GCAN) has submitted a clinical trial application to the Israel Ministry of Health for approval of Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy.
PureTech Health Confirms ‘Possible’ Merger With Nektar Therapeutics
PureTech Health plc (NASDAQ:PRTC) has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ:NKTR). In April, Nektar Therapeutics…
Alnylam’s Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
The FDA approved a label expansion for Alnylam Pharmaceuticals Inc’s (NASDAQ:ALNY) for Oxlumo (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now…
BioMarin Lays Off 4% Of Its Workforce To ‘Simplify’ The Company
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) will redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch…
Accolade Posts Narrower Quarterly Loss, Tightens Annual Sales Guidance
Accolade Inc (NASDAQ:ACCD) reported Q2 FY23 sales of $87.6 million, up 20% Y/Y, beating the consensus of $82.86 million and…
Amid FDA Dispute, Juul Labs Cancels Overseas Expansion Plans, Refinances Some Debt
Juul Labs Inc's CEO, K.C. Crosthwaite, said the company is taking all necessary steps to keep it afloat. Altria Group Inc (NYSE: MO) has a minority stake in the company.